Class Action Lawsuit Overview: A Call to Investors
In light of recent developments, Kirby McInerney LLP is reaching out to investors regarding a class action lawsuit concerning Applied Therapeutics, Inc. (NASDAQ: APLT). This lawsuit focuses on shareholders who acquired stock between specific dates in 2024. If you are one of the investors affected, it's essential to understand your rights and the potential implications of this legal action.
Details of the Class Action Filed
The class action has been filed in the Southern District of New York, prompting concern among investors. Those who purchased securities during the designated Class Period should be aware that they have until a specified deadline to apply as lead plaintiffs in this case. This process is crucial for those who wish to actively participate in the lawsuit and assert their rights.
Key Events Leading to the Lawsuit
On November 27, 2024, Applied Therapeutics made headlines by announcing it had received a Complete Response Letter (CRL) related to its New Drug Application for its lead product candidate, govorestat. This news raised significant alarms, leading to a dramatic decrease in stock value—approximately 76%—causing investors to reassess their positions and potential losses.
FDA Warning Letter Ignites Further Concerns
Adding to the turmoil, a warning letter from the FDA disclosed serious issues regarding the company’s clinical trials. This correspondence highlighted problems with electronic data capture and a dosing error, further informing investors about the critical nature of the situation. As a result, Applied Therapeutics shares experienced another significant drop, compounding the losses shareholders faced during this turbulent period.
Misleading Statements Alleged in the Lawsuit
The lawsuit contends that throughout the investment period, the company's representatives misled investors with overly positive statements regarding the state of their clinical trials. This misleading information obscured crucial facts, particularly around the FDA's findings, leaving investors with unresolved questions about their investments.
Protecting Your Rights as an Investor
If you have invested in Applied Therapeutics, now is the time to gather as much information as possible. Engaging with legal professionals who specialize in securities litigation can provide you with insights into your situation and the potential steps you can take to safeguard your interests. Company representatives from Kirby McInerney LLP stand ready to assist those seeking clarity and guidance.
About Kirby McInerney LLP
Kirby McInerney LLP is a law firm based in New York that focuses on representing plaintiffs in securities, antitrust, whistleblower, and consumer litigation. Their commitment to protecting shareholder rights has led to recoveries worth billions, shaping their reputation as a formidable advocate for investors. More information is available on their official website, which details their practice areas and success stories.
Frequently Asked Questions
What is the main purpose of the class action lawsuit?
The class action lawsuit seeks to hold Applied Therapeutics accountable for misleading investors during the specified Class Period regarding significant issues with their clinical trials and FDA communications.
Who can participate in the lawsuit?
Investors who purchased or acquired Applied Therapeutics securities during the designated Class Period are eligible to participate in the lawsuit and may apply to be lead plaintiff.
How much has the stock price dropped recently?
Since the announcement of the Complete Response Letter on November 27, 2024, the stock price of Applied Therapeutics dropped significantly, reflecting a decline of approximately 76% from $8.57 to $2.03 per share.
Who should I contact for more information?
Investors seeking more information should contact Thomas W. Elrod of Kirby McInerney LLP, who is available to discuss your rights and interests concerning the class action.
What should I do if I was affected?
If you believe you have been impacted by misleading information from Applied Therapeutics or wish to explore your involvement in the class action, it is advisable to consult with legal professionals who specialize in securities litigation.
